Analysts Set Century Therapeutics, Inc. (NASDAQ:IPSC) Target Price at $4.00

Shares of Century Therapeutics, Inc. (NASDAQ:IPSC) have been given a consensus rating of “Hold” by the seven research firms that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $4.25.

Several equities research analysts have recently issued reports on the company. Piper Sandler raised their price target on Century Therapeutics from $2.00 to $4.00 and gave the company an “overweight” rating in a research report on Tuesday, January 20th. TD Cowen assumed coverage on Century Therapeutics in a research report on Wednesday, February 25th. They issued a “buy” rating on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Century Therapeutics in a research report on Monday, April 6th. Zacks Research downgraded Century Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, March 12th. Finally, Wall Street Zen raised Century Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, March 7th.

Insider Activity

In other news, insider Gregory Russotti sold 10,076 shares of the firm’s stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $2.55, for a total value of $25,693.80. Following the sale, the insider directly owned 515,427 shares of the company’s stock, valued at approximately $1,314,338.85. This trade represents a 1.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders sold 17,921 shares of company stock valued at $45,458 over the last 90 days. Company insiders own 4.37% of the company’s stock.

Hedge Funds Weigh In On Century Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Cannon Global Investment Management LLC bought a new position in Century Therapeutics during the first quarter valued at about $111,000. Adage Capital Partners GP L.L.C. bought a new position in Century Therapeutics during the fourth quarter valued at about $1,829,000. Spruce Street Capital LP bought a new position in Century Therapeutics during the fourth quarter valued at about $1,414,000. Geode Capital Management LLC increased its stake in Century Therapeutics by 2.4% during the fourth quarter. Geode Capital Management LLC now owns 456,115 shares of the company’s stock valued at $454,000 after acquiring an additional 10,806 shares during the period. Finally, Citadel Advisors LLC increased its stake in Century Therapeutics by 64.1% during the third quarter. Citadel Advisors LLC now owns 360,825 shares of the company’s stock valued at $180,000 after acquiring an additional 140,891 shares during the period. 50.20% of the stock is currently owned by institutional investors.

More Century Therapeutics News

Here are the key news stories impacting Century Therapeutics this week:

• Positive Sentiment: HC Wainwright maintains a “Buy” rating and a $5.00 price target, which supports upside if clinical or partnership milestones are met. HC Wainwright note (Buy, $5 target)
• Neutral Sentiment: The firm released a full schedule of quarterly estimates (Q1–Q4 2026 and Q1–Q4 2027), showing fairly steady per-quarter losses in the ~$0.21–$0.23 range — useful guidance but not a near-term catalyst by itself. HC Wainwright quarterly EPS schedule
• Negative Sentiment: HC Wainwright’s FY2026 EPS forecast of ($1.00) and FY2027 forecast of ($0.89) are materially worse than the consensus (~($0.44)), implying deeper cash burn, greater financing/dilution risk and downward pressure on valuation. That divergence is the likely driver of the share weakness. HC Wainwright downside EPS outlook

Century Therapeutics Stock Performance

Shares of NASDAQ:IPSC opened at $2.26 on Tuesday. The company has a market cap of $406.94 million, a P/E ratio of -16.14 and a beta of 1.66. The stock’s 50-day moving average is $2.29 and its 200-day moving average is $1.47. Century Therapeutics has a 52-week low of $0.44 and a 52-week high of $3.04.

Century Therapeutics (NASDAQ:IPSC) last issued its quarterly earnings results on Thursday, March 12th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.04. As a group, equities analysts predict that Century Therapeutics will post -0.63 EPS for the current year.

Century Therapeutics Company Profile

Century Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of allogeneic cell therapies for cancer. Utilizing induced pluripotent stem cell (iPSC) technology, the company engineers “off-the-shelf” natural killer (NK) and T cell candidates designed to target hematologic malignancies and solid tumors. By harnessing iPSC-derived immune cells, Century aims to overcome challenges associated with patient-derived therapies, such as manufacturing variability and treatment delays.

The company’s proprietary platform integrates gene editing, synthetic biology and scalable cell expansion processes to generate a pipeline of product candidates.